drugset
drugset / Trial / NCT03684265

A Study to Compare the Amount of Meloxicam in the Blood When it is Taken as Capsules or as Tablets

NCT03684265 ↗

Phase 1 Completed 26 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

The primary objective of the study is to investigate the relative bioavailability of Movalis capsules 15 mg (Test, T) versus Movalis tablets 15 mg (Reference, R). The secondary objective of the study is to establish bioequivalence of Movalis capsules 15 mg (Test, T) versus Movalis tablets 15 mg (Reference, R).

Timeline

Start
2018-10-05
Primary completion
2018-10-30
Completion
2018-11-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Meloxicam Small molecule 15 mg Oral

Indications

No indication recorded.